Radiotherapy Trials

1. High Dose or Standard Dose Radiation Therapy and Chemotherapy with or without Cetuximab in Treating Patients with Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00533949

This randomized phase III trial is studying high-dose or standard-dose radiation therapy given together with chemotherapy with or without cetuximab to see how well they work in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery and if Overall Survival is improved.
Quebec
Hopital Notre Dame, Montreal

Saskatchewan
Saskatoon Cancer Centre, Saskatoon
Allan Blair Cancer Centre, Regina

Ontario
Princess Margaret Hospital, Toronto

Manitoba
Cancer Care Manitoba, Winnipeg

Alberta
Tom Baker Cancer Centre, Calgary

2. Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY)

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01351116

Purpose: A trial to improve the quality of life of patients with advanced non-small cell lung cancer (NSCLC) by evaluating the symptomatic improvements in lung cancer patients receiving external radiation with or without high dose internal radiation.

British Columbia
Abbotsford Centre, Abbotsford

Ontario
Juravinski Cancer Centre, Hamilton
Cancer Centre of Southeastern Ontario, Kingston
Grand River Regional Cancer Centre, Kitchener
London Regional Cancer Centre, London
Princess Margaret Cancer Centre, Toronto
Windsor Regional Hospital Cancer Centre, Windsor

Quebec
L'Hotel-Dieu de Quebec, Quebec City



3. Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours

ClinicalTrials.gov Identifier: NCT00351962

Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.
Alberta
Tom Baker Cancer Centre, Calgary

4. Cisplatin, Etoposide, and Two Different Schedules of Radiation Therapy in Treating Patients with Limited Stage Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00433563

Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which schedule of radiation therapy is more effective when given together with chemotherapy in treating small cell lung cancer.
This randomized phase III trial is studying two different schedules of radiation therapy to compare how well they work when given together with cisplatin and etoposide in treating patients with limited stage small cell lung cancer.
Ontario
Princess Margaret Hospital, Toronto

5. Stereotactic Body Radiation Therapy in Treating Patients with Stage I Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00750269

Stereotactic body radiation therapy may be able to send x-rays directly to the tumour and cause less damage to normal tissue.
This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with stage I non-small cell lung cancer.
Ontario
Princess Margaret Hospital, Toronto

6. Individual Boosting in Non-Small Cell Lung Cancer Using Hypofraction, Intensity-modulated Radiation Therapy and Respiratory Gating

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT00690963

The purpose of this study is to determine whether the combination of custom designed intensity-modulated radiotherapy (based on individual tumor anatomy) with regular chemotherapy, will be safe enough to allow further intensification of radiation treatment.
Alberta
Cross Cancer Institute, Edmonton

7. Short Neoadjuvant Hemithoracic IMRT for MPM

ClinicalTrials.gov Identifier: NCT00797719

A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma.
Ontario
University Health Network, Toronto

8. Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
 
ClinicalTrials.gov Identifier: NCT01426841

This study is intended to assess the feasibility of adjusting a radiation plan during its course to accommodate for a shrinking tumour target. The investigators hypothesize that an adaptive radiotherapy (RT) planning strategy for small cell lung cancer (SCLC) patients with chest-confined disease will allow for safe delivery of higher doses of chest RT than a non-adaptive RT planning approach without subjecting normal critical structures to unacceptable doses of radiotherapy.
Alberta
Cross Cancer Institute

9. Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients (LUSTRE)

ClinicalTrials.gov Identifier: NCT01968941

A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy.
Ontario
Juravinski Hospital Cancer Center, Hamilton
Walker Family Cancer Centre, St. Catharines

British Columbia
Vancouver Island Cancer Centre, Victoria

Alberta
Tom Baker Cancer Centre, Calgary

Manitoba
Cancer Care Manitoba, Winnipeg

Quebec
Hospital Notre Dame, Montreal
Hôpital Maisonneuve-Rosemont, Montreal
Montreal General Hospital McGill, Montreal

Saskatchewan
Saskatoon Cancer Centre, Saskatoon

10. Stereotactic Radiotherapy (SBRT) of Lung Metastasis

ClinicalTrials.gov Identifier: NCT01803542

The purpose of this institutional protocol is to offer SBRT to selected patients in a controlled environment to refine treatment techniques (including dose/fractionation schedules) and standardize follow-up.
Ontario
Princess Margaret Hospital, Toronto

11. Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)

ClinicalTrials.gov Identifier: NCT01279408

The aim of the study is to assess current practice within PROP &lung teams, for treating asymptomatic patients with centrally located non-small cell lung cancer (NSCLC), and to observe outcomes for those patients receiving immediate or deferred RT. This is a prospective cohort trial. Patients will be managed by immediate radiotherapy (RT) or a deferred approach according to physicians' individual current clinical practice.
Ontario
University Health Network, Toronto

12. Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial

ClinicalTrials.gov Identifier: NCT02002052

Functional lung avoidance radiotherapy aims to reduce radiotherapy dose to regions of functioning lung, instead depositing dose in areas of lung that are not well-ventilated.
Ontario
London Health Sciences Center, London

13. A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02136355

Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. The study combines SABR and surgery to treat non-small cell lung cancer. SABR will be done first, with surgery done approximately 10 weeks later. There will be some extra imaging done before and after the SABR. The purpose of this study is to determine how effective SABR is in killing the cancer cells, and if SABR can help make surgery more effective.
Ontario
London Regional Cancer Program, London

14. Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously (VOLUMES)

ClinicalTrials.gov Identifier: NCT01543672

Treatment of larger tumour volumes or ≥ 2 lung metastases simultaneously in lung cancer patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation study.
Ontario
Princess Margaret Hospital, Toronto

15. Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (LINNEARRE-I)

ClinicalTrials.gov Identifier: NCT02433574

This is a phase I study that investigates the feasibility and safety of delivering Stereotactic Body Radiotherapy (SBRT) to patients with locally invasive NSCLC (cT3-4, N0-1) who are at risk for incomplete resection. Twenty patients with NSCLC will be treated with SBRT followed by surgery and appropriate adjuvant therapy. Patients will be divided into groups, of 5 patients each, treated with escalating doses (35, 40, 45 and 50 Gy) in 10 daily fractions. The primary outcome is the feasibility i.e. the ability to complete safely SBRT and surgery (within 6 weeks). Secondary outcomes include acute and late adverse events, R0/R1/R2 rates and secondary surrogates of feasibility. If successful, this study will lead to further evaluation of pre-operative SBRT in NSCLC.
Ontario
Juravinski Cancer Center, Hamilton

16. Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT01480973

SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately describe, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
Ontario
University Health Network, Toronto

17. Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC)

ClinicalTrials.gov Identifier: NCT02756793

A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive non-small cell lung cancer. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions. Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
British Columbia
BC Cancer Agency Fraser Valley, Surrey

Ontario
London Regional Cancer Program, London

18. Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy (PET-BOOST)

ClinicalTrials.gov Identifier: NCT02788461

A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost. All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan within two weeks prior to starting treatment. The primary outcome is to determine if dose escalation to metabolically active tumour subvolumes will reduce local-regional failure rate at 2 years.
Ontario
London Regional Cancer Program, London
Princess Margaret Cancer Centre, Toronto

19. Phase II Trial of Individualized Lung Tumour Stereotactic Ablative Radiotherapy (iSABR)

ClinicalTrials.gov Identifier: NCT01463423

A research study using a method of treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumours with SABR based on tumour-specific factors.
Ontario
Princess Margaret Cancer Center, Toronto

20. Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

ClinicalTrials.gov Identifier: NCT02635009

This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has spread outside of the lung in which it began or to other parts of the body (extensive stage). Radiation therapy uses high energy x-rays to kill tumour cells and shrink tumours. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Quebec
L'Hotel-Dieu de Quebec, Quebec City

21. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) forLung Cancer (STABLE-MATES)

ClinicalTrials.gov Identifier: NCT02468024

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial.
Quebec
Montreal